Sutro Biopharma Inc

Sutro Biopharma Inc operates with a negative equity position of -$132.45 million and a cash and equivalents balance of $58.13 million, indicating a liquidity position that is constrained by its negative net worth. The company's liquidity ratio of 2.01 suggests it can cover its short-term liabilities with its current assets, but the absence of long-term debt and the negative equity position highlight structural capital challenges. The enterprise value to revenue ratio of 4.38 indicates a premium valuation relative to its current revenue base, which may reflect market expectations of future growth or therapeutic pipeline potential. The company's profitability metrics are negative, with a net loss of $191.09 million and an operating loss of $158.37 million, which is consistent with the typical financial profile of a clinical-stage biopharmaceutical firm. The return on equity of 1.44% is positive but extremely low, and the return on assets of -1.0993% reflects the company's inability to generate returns from its asset base. These metrics are not directly comparable to industry medians due to the company's pre-revenue or early-stage status, but they underscore the capital-intensive nature of its operations. Sutro Biopharma Inc's revenue is not segmented by product or geographic region in the available data, but the company's focus on protein therapeutics for cancer and autoimmune diseases suggests a concentration in therapeutic areas rather than geographic markets. The absence of detailed segment data limits the ability to assess revenue diversification or geographic exposure. The company's growth trajectory is speculative, as it has not yet achieved profitability and is currently reporting a net loss. Analysts have provided a mean price target of $33.30, which is a 9.0% increase from the current market price of $30.62, but the wide range of price targets from $9.00 to $55.00 indicates significant uncertainty about the company's future performance. The mean recommendation of 2.08 (on a scale from 1 to 5) suggests a generally positive outlook, but the presence of a single "Hold" recommendation and the absence of "Strong Sell" ratings indicate a cautious stance among analysts. The risk assessment for Sutro Biopharma Inc indicates low liquidity and dilution risk, with no immediate filing-based flags detected. However, the company's negative equity and operating cash flow of -$177.23 million suggest a high dependency on external financing to fund operations. The dilution risk is currently low, but the company's need for continued capital infusions could increase the likelihood of future dilution events. Recent events for Sutro Biopharma Inc include the publication of its latest financial data, which shows a continuation of its net loss and negative operating cash flow. The company has not disclosed any recent major clinical trials, partnerships, or regulatory milestones in the provided data, which limits the ability to assess recent operational developments.